1. In Vivo
  2. >>Innovation

A Virtuous Cycle: What The Immuno-Oncology Revolution Means For Other Disease Areas

 
• By Emily Hayes

Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.

Shutterstock: Ralwel
• Source: Shutterstock: Ralwel

Approval in 2011 of Bristol-Myers Squibb Co.'s CTLA-4 checkpoint inhibitor Yervoy (ipilimumab) in melanoma signaled the start of the immunotherapy revolution in the field of cancer therapy, followed by the PD-1 inhibitors and with new mechanisms nearing the market. Data presented at the Society for Immunotherapy and Cancer (SITC) annual meeting in November revealed that PD-1/L1 inhibitors such as Bristol's Opdivo (nivolumab) and Merck & Co. Inc.'s Keytruda (pembrolizumab) are being tested in about 1,500 clinical trials, of which 74% are evaluating combination approaches with other immunotherapies and traditional targeted agents. (Also see "Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well" - Scrip, 14 November, 2017.)

Development has been fueled by high unmet need and regulatory willingness to speed approvals for drugs aimed at life-threatening diseases....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By David Wild

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

BioBytes: AI-Related Deals In Q2 ‘25

 
• By David Wild

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Thinking Outside The BIOX: Bioxodes Takes Novel Approach To Intracerebral Hemorrhage

 
• By Jo Shorthouse

Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.

More from In Vivo

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By David Wild

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

BioBytes: AI-Related Deals In Q2 ‘25

 
• By David Wild

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By Eleanor Malone, Edwin Elmhirst, and Kosh Naran

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.